SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Recursion Pharmaceuticals Phase 2 Shows 47% Median Polyp Burden Reduction

The Phase 2 update also says 85% of evaluable patients were below baseline after 12 weeks off treatment.

RXRX

Related stories